Aclaris' mixed PhIIb eczema data; Amgen licenses Xeris' tech; Bolden Tx secures funding

2024-01-10

临床结果临床2期临床失败

Aclaris Therapeutics reported mixed results for its JAK inhibitor JAK inhibitor in a Phase IIb eczema study . The biotech seeks a partner for next steps. Aclaris announced Wednesday that at four weeks, its JAK 1/3 inhibitor ATI-1777 significantly reduced scores from baseline on a measure of eczema severity compared to placebo in patients who received the treatment twice daily. However, in those who received the treatment once a day, ATI-1777 failed to hit statistical significance. Aclaris’ shares $ACRS dropped about 25% Wednesday morning to below $1. Aclaris’ share value has fallen nearly 95% over the past year after a series of clinical trial fails, and in December, the biotech laid off just under half of its staff . — Lei Lei Wu

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构